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Abstract
Background Potentially inappropriate antipsychotic use in
long-term care (LTC) facilities has been the focus of sig-
nificant policy and clinical attention over the past 20 years.
However, most initiatives aimed at reducing the use of
these medications have overlooked assisted living (AL)
settings.
Objective We sought to compare the prevalence of
antipsychotic use (including potentially inappropriate use)
among older AL and LTC residents and to explore the
resident and facility-level factors associated with use in
these two populations.
Methods We performed cross-sectional analyses of 1089
residents (mean age 85 years; 77% female) from 59 AL
facilities and 1000 residents (mean age 85 years; 66%
female) from 54 LTC facilities, in Alberta, Canada.
Research nurses completed comprehensive resident
assessments at baseline (2006–2007). Facility-level factors
were assessed using standardized administrator interviews.
Generalized linear models were used to estimate odds
ratios for associations, accounting for clustering by facility.
Results Over a quarter of residents in AL (26.4%) and
LTC (31.8%) were using antipsychotics (p = 0.006).
Prevalence of potentially inappropriate use was similar in
AL and LTC (23.4 vs. 26.8%, p = 0.09). However, among
users, the proportion of antipsychotic use deemed poten-
tially inappropriate was significantly higher in AL than
LTC (AL: 231/287 = 80.5%; LTC: 224/318 = 70.4%; p =
0.004). In both settings, comparable findings regarding
associations between resident characteristics (including
dementia, psychiatric disorders, frailty, behavioral symp-
toms, and antidepressant use) and antipsychotic use were
observed. Few facility characteristics were associated with
overall antipsychotic use, but having a pharmacist on staff
(AL), or an affiliated physician (LTC) was associated with
a lower likelihood of potentially inappropriate antipsy-
chotic use.
Conclusion Our findings illustrate the importance of
including AL settings in clinical and policy initiatives
aimed at reducing inappropriate antipsychotic use among
older vulnerable residents.
Electronic supplementary material The online version of this
article (doi:10.1007/s40266-016-0411-0) contains supplementary
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Key Points
Overall and potentially inappropriate antipsychotic
use were common in both assisted living (26.4 and
23.4%) and long-term care (31.8 and 26.8%)
settings.
Correlates of antipsychotic use were similar among
assisted living and long-term care residents,
including potentially concerning associations with
dementia, frailty, and other psychotropic medication
use.
This study provides evidence to support the
expansion of initiatives aimed at reducing
inappropriate antipsychotic use in long-term care
settings to include assisted living facilities.
1 Introduction
The widespread use of antipsychotic medications in long-
term care (LTC) facilities has been the focus of consider-
able clinical, research, and policy attention [1–4]. This
attention has largely been fueled by doubts regarding the
effectiveness of antipsychotics coupled with concerns
about associated adverse effects [5], including death [6]
and stroke [7, 8], particularly when used by individuals
with dementia [9–11].
Government-approved indications for antipsychotics
vary by country [12, 13] and have evolved over time with
emerging research on older and younger populations
[14, 15]. Health Canada approved indications specific to
adults include use for schizophrenia and related psychotic
disorders, bipolar disorders, and major depression as well
as the short-term use of risperidone for aggression and
psychotic symptoms in individuals with severe dementia of
the Alzheimer type [16]. Regulatory bodies in both Canada
and USA have issued warnings regarding the increased risk
of death associated with the use of antipsychotics in older
adults with dementia [17, 18]. Despite these warnings and
reports that the drugs offer limited benefit to those with
dementia [19–21], various antipsychotics are frequently
prescribed for unapproved indications, often to manage
behavioral concerns associated with dementia [14, 22, 23].
Another major concern associated with antipsychotics is
that their use is often continued long term in continuing
care settings [24], and frequently occurs without adequate
medication review to re-assess appropriateness [25].
Both the Canadian Coalition for Seniors Mental Health
[22] and Choosing Wisely Canada [26] encourage the use
of non-pharmacological interventions to address behavioral
and psychological symptoms of dementia prior to the
prescription of antipsychotics. With these recommenda-
tions, the aim of both groups is to limit adverse outcomes
related to the use of antipsychotics among those with
dementia, while recognizing that they may be the most
effective option in some cases [21].
The Canadian Foundation for Healthcare Improvement
is supporting efforts to reduce potentially inappropriate
antipsychotic use (i.e., use among those without a diagnosis
of psychoses) through staff training and accreditation ini-
tiatives in LTC facilities [27]. As with similar initiatives in
USA and Canada, [3, 28, 29] their focus is to enhance
understanding of the drivers of antipsychotic use among
LTC residents with the aim of reducing inappropriate use
through targeted interventions [22]. However, compared
with the LTC sector, there has been little research
exploring antipsychotic use among older residents of
assisted living (AL) settings, with no studies done in
Canada. As recently noted by Zimmerman and colleagues
[30], AL facilities have typically not been included in
initiatives aimed at reducing inappropriate antipsychotic
use within the continuing care sector.
AL facilities aim to offer supportive care, emphasizing
autonomy and privacy in a home-like setting. AL residents
typically have substantial health needs albeit fewer com-
pared with LTC residents. Data from USA and Canada
indicate that rates of dementia are high in AL (upwards of
60%) [31, 32]. Within some regions, AL is viewed as a
substitute for LTC facility-based care [33, 34], but staffing
levels are often lower with fewer skilled staff members per
resident [35–37].
With current research limitations in mind, the objectives
of this study were to: (1) examine the prevalence of
antipsychotic use, including potentially inappropriate use
(using a definition currently employed by Canadian health
and quality monitoring organizations) among older (aged
65? years) residents of AL and LTC facilities in Alberta,
Canada; and, (2) explore and compare the resident and
facility-level characteristics associated with antipsychotic
use in these two care settings. We hoped to provide
empirical data to assess whether AL facilities should be
included in initiatives aimed at reducing inappropriate
antipsychotic use among continuing care residents.
2 Methods
2.1 Analytic Sample
This investigation used data from the Alberta Continuing
Care Epidemiological Studies (ACCES), a longitudinal
study of older (aged 65? years) residents of designated
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(publicly funded) assisted living (DAL) and LTC facilities
in Alberta, Canada who were assessed and followed from
2006 to 2009. Resident assessments as well as interviews
with family caregivers and facility representatives were
conducted. For both settings, residents in participating sites
were excluded if they were \65 years of age, recently
admitted (\21 days), receiving palliative care (expected
survival\6 months), and/or their participation was other-
wise deemed inappropriate by staff or family. Approxi-
mately 18% of DAL (52/291) and 4% of LTC (9/227)
residents were ineligible based on this last criterion, which
included those in hospital at baseline. For residents capable
of making their own informed decisions (as reported by
facility representatives), written informed consent for par-
ticipation was obtained by research nurses after an initial
independent approach and introduction by facility staff. For
residents with moderate to severe cognitive impairment (as
determined by facility representatives) or with an enacted
personal directive, written consent was obtained from
designated surrogate decision makers.
DAL study participants were 1089 of 1510 eligible res-
idents (72.1% response rate) from 59 participating (out of
60 eligible) DAL facilities. Of those not enrolled, 339
(22.5% of eligible residents) refused to participate and for
the remaining 82 (5.4%) their legally designated surrogate
could not be contacted. Age and sex were available for 364
(86.5%) of the 421 nonparticipants and showed a similar
distribution (mean age 84.4 ± 7.1 years, 74% women) to
that of participants (mean age 84.9 ± 7.3 years, 77%
women). At the time of the ACCES, there were consider-
ably more LTC than DAL residents potentially eligible for
participation. Consequently, a random sample of 1731 eli-
gible LTC residents was drawn from 54 facilities with a
final sample of 1000 participants (57.8% response rate).
Age and sex were available for 665/731 (91%) of nonpar-
ticipants and showed a similar distribution (mean age 84.7
± 7.5 years, 67% women) to participants (mean age 84.9 ±
7.6 years, 66% women). Additional information regarding
the ACCES study has been previously published [38–40].
Ethical approval for the ACCES study was originally
obtained from the University of Calgary Conjoint Health
Research Ethics Board, the University of Alberta Research
Ethics Board, and the University of Lethbridge Human
Subject Research Committee. This ACCES sub-study was
granted ethics approval by the University of Waterloo,
Office of Research Ethics.
2.2 Resident Characteristics
Trained research nurses administered the Resident
Assessment Instrument for Assisted Living or LTC Facility
(interRAI-AL or interRAI-LTCF) among DAL and LTC
residents (respectively) at baseline (2006–2008). These
validated assessment tools capture information on resi-
dents’ sociodemographic characteristics, health conditions,
physical and cognitive status, behavioral problems, and use
of medications and services [41–43]. A comprehensive list
of all prescribed and non-prescribed medications taken by
the resident over the previous 3 days was captured by
research nurses as part of the assessment through consul-
tation with the resident and staff members (with exami-
nation of drug containers and facility drug lists where
available and current).
Resident characteristics examined included age, sex,
dementia diagnosis (along with treatment status by
acetylcholinesterase inhibitors and/or memantine), diag-
nosis of depression, diagnoses of other psychiatric condi-
tions (schizophrenia, bipolar disorder, anxiety), presence of
delusions and/or hallucinations, diagnoses of cardiovascu-
lar conditions (hypertension, coronary heart disease, con-
gestive heart failure, peripheral vascular disease, cardiac
dysrhythmia, valvular stenosis, venous thromboembolism
or lipid abnormalities), diagnoses of cerebrovascular con-
ditions, number of medications (excluding antipsychotics),
history of falls, length of stay in facility, location prior to
admission, history of inpatient hospitalizations and/or
emergency department visits, frailty status (based on
comparable 86-item [DAL] and 83-item [LTC] Frailty
Index [44, 45] measures derived from the respective
interRAI assessment tools and with cut-off points of[0.3
for frail, 0.2–0.3 for pre-frail, and \0.2 for robust),
aggressive behavior (modeled on the interRAI-derived
Aggressive Behavior Scale [46]), elopement attempts,
wandering behavior, use of physical restraints, use of
antidepressant medication, use of anxiolytic medication,
and use of hypnotic and/or sedative medication.
The main outcome was current antipsychotic use,
defined as use of one or more medications classified as an
antipsychotic (included those used pro re nata) by the
Anatomical Therapeutic Classification system, based on
the assessment of medication use performed by study
nurses as described above.
Sensitivity analyses were conducted to examine the
prevalence and correlates of potentially inappropriate
antipsychotic use in both settings, and to compare these
findings with those for overall antipsychotic use. For these
analyses, potentially inappropriate antipsychotic use was
defined using criteria adopted by the Canadian Institute for
Health Information [47] to permit a comparison of our
findings with existing Canadian data. Specifically,
antipsychotic use was defined as being potentially inap-
propriate when it occurred in the absence of a diagnosis of
psychosis (schizophrenia) or Huntington’s disease, and/or
symptoms of delusions and/or hallucinations. Residents
with end-stage disease or receiving palliative care were
excluded from the ACCES study.
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2.3 Facility Characteristics
For each facility, an administrator, manager, or director of
care (i.e., someone familiar with the facility and with direct
knowledge about the residents) was surveyed about mid-
way during the 1-year follow-up period of the full ACCES
study regarding baseline facility characteristics. Facility-
level variables considered included the presence of desig-
nated dementia beds in the facility, for-profit/not-for-profit
ownership, status as part of an AL and/or LTC chain,
availability of other levels of care on site (including LTC
and acute care beds), availability of licensed practical
nurses and/or registered nurses on site 24 h a day/7 days a
week, affiliation of a physician with facility, involvement
of a pharmacist within the past month, and the health
region in which the facility was located. It should be
noted that health region (as defined at the time of the
ACCES study) captures provincial variation in health
policies, services, facility types as well as community size
and urban/rural status.
2.4 Analytical Approach
Descriptive analyses were conducted to examine the dis-
tribution of baseline resident and facility characteristics
(overall and associated with antipsychotic use) among
DAL and LTC residents. Resident and facility-level char-
acteristics were assessed for their association with preva-
lent antipsychotic use in bivariate analyses. Categorical
versions of continuous variables were derived using cut-off
points based on the sample distribution and previous
ACCES reports [38, 40]. These associations were further
examined using generalized linear models with a binomial
distribution and logit link to estimate odds ratios (ORs),
also accounting for clustering with generalized estimating
equations. Variables considered relevant based on the ini-
tial age/sex-adjusted models (p\ 0.05) and existing liter-
ature [48–50] were considered for inclusion in a
multivariable model to adjust for potential confounders and
identify variables independently associated with use of
antipsychotics. Resident variables included in the final
model were assessed using bi-directional stepwise selec-
tion; those that remained significant with p values\0.10
were retained in the final model to permit comparison
across settings for selected variables, including variables
potentially limited by small cell sizes in a particular setting.
Owing to relatively high correlations among facility char-
acteristics, each facility-level variable was examined in a
separate model adjusting for all relevant resident-level
variables.
For the LTC models, frailty status was considered as a
binary variable (with robust and pre-frail residents grouped
compared with frail residents), owing to the small sample
of robust LTC residents using antipsychotics (n = 14).
All analyses were carried out using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
3 Results
In both DAL and LTC, the mean age of residents was 84.9
years and most were women (77 and 66%, respectively)
(Table 1). Overall antipsychotic use at baseline was 26.4%
(n = 287) in DAL and 31.8% (n = 318) in LTC (p = 0.006).
Among DAL and LTC residents, 57.6 and 70.8% had a
diagnosis of dementia (p\0.0001), 18.5 and 22.2% had a
diagnosis of a psychiatric disorder (schizophrenia, bipolar
disorder, anxiety) [p = 0.0458], and 29.2 and 65.9% were
assessed as having some degree of aggressive behavior
(Aggressive Behaviour Scale [ABS] score [0) [p \
0.0001], respectively. After excluding residents with
schizophrenia, Huntington’s disease, delusions and/or hal-
lucinations, the prevalence of potentially inappropriate
antipsychotic use was 23.4% (n = 231/989) in DAL, with a
slightly higher prevalence of 26.8% (n = 224/835) in LTC
(p = 0.088). Most antipsychotic users in both settings met
criteria for potentially inappropriate use, with a signifi-
cantly greater (p = 0.004) proportion among users in DAL
(231/287 or 80.5%) compared with LTC (224/318 or
70.4%).
The distribution of resident and facility-level charac-
teristics among DAL and LTC residents by antipsychotic
use are shown in Tables 1 and 2, respectively. Within each
setting, antipsychotic users had a lower mean age, and the
proportion of residents using antipsychotics was signifi-
cantly higher among residents with dementia, psychiatric
disorders, depression, delusions and/or hallucinations,
highest frailty level, more severe aggressive behaviors, and
those who exhibited elopement attempts or threats, wan-
dered, or used antidepressants, compared with residents
without these conditions. Use of antipsychotic medication
was also significantly associated with anxiolytic use, hyp-
notic and/or sedative use, physical restraint use, and history
of falls among LTC (but not DAL) residents. Among DAL
residents, antipsychotic use was significantly less prevalent
in those with a reported diagnosis of cardiovascular or
cerebrovascular disease whereas among LTC residents, use
was significantly less prevalent among those with a diag-
nosis of cerebrovascular disease only. Antipsychotic use
was more common among residents who had lived in DAL
for a longer period of time, but no such association was
observed among LTC residents.
Table 3 presents findings regarding resident character-
istics associated with antipsychotic use from fully adjusted
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Table 1 Resident characteristics (DAL vs. LTC), overall and in relation to antipsychotic use (row%)
Characteristic n (%),
unless otherwise noted
DAL residents LTC residents
Total sample
(n = 1089)
Antipsychotic
users (n = 287
[26.4%])
Antipsychotic
non-users
(n = 802 [73.6%])
Total sample
(n = 1000)
Antipsychotic
users (n = 318
[31.8%])
Antipsychotic
non-users
(n = 682 [68.2%])
Sociodemographic
Age, years
Mean ± SD 84.9 ± 7.3 84.2 ± 7.3 85.2 ± 7.3** 84.9 ± 7.6 83.9 ± 7.5 85.4 ± 7.6*
65–79 272 (25.0) 84 (30.9) 188 (69.1) 231 (23.1) 89 (38.5) 142 (61.5)*
80–85 285 (26.2) 78 (27.4) 207 (72.6) 256 (25.6) 83 (32.4) 173 (67.6)
86–89 247 (22.7) 61 (24.7) 186 (75.3) 216 (21.6) 68 (31.5) 148 (68.5)
C90 285 (26.1) 64 (22.5) 221 (77.5) 297 (29.7) 78 (26.3) 219 (73.7)
Sex
Male 254 (23.3) 66 (26.0) 188 (74.0) 343 (34.3) 113 (32.9) 230 (67.1)
Female 835 (76.7) 221 (26.5) 614 (73.5) 657 (65.7) 205 (31.2) 452 (68.8)
Facility length of stay, months
Mean ± SD 23.0 ± 19.7 25.4 ± 21.9 22.1 ± 18.9* 36.8 ± 39.2 36.1 ± 34.1 37.1 ± 41.4
\12 377 (34.6) 80 (21.2) 297 (78.8)* 264 (26.4) 74 (28.0) 190 (72.0)
12–24 314 (28.8) 86 (27.4) 228 (72.6) 222 (22.2) 75 (33.8) 147 (66.2)
[24 398 (36.6) 121 (30.4) 277 (69.6) 514 (51.4) 169 (32.9) 345 (67.1)
Location prior to admission
Home 409 (37.6) 102 (24.9) 307 (75.1) 148 (14.8) 49 (33.1) 99 (66.9)
Hospital 326 (29.9) 90 (27.6) 236 (72.4) 445 (44.6) 139 (31.2) 306 (68.8)
Institution (AL/LTC/other) 354 (32.5) 95 (26.8) 259 (73.2) 404 (40.5) 127 (31.4) 277 (68.6)
Health and functional status
Dementia and treatment statusa
No dementia 462 (42.4) 62 (13.4) 400 (86.6)* 292 (29.2) 53 (18.2) 239 (81.8)*
Dementia, not treated 361 (33.2) 127 (35.2) 234 (64.8) 557 (55.7) 197 (35.4) 360 (64.6)
Dementia, treated 266 (24.4) 98 (36.8) 168 (63.2) 151 (15.1) 68 (45.0) 83 (55.0)
Psychiatric diagnosesb
No 888 (81.5) 202 (22.7) 686 (77.3)* 778 (77.8) 206 (26.5) 572 (73.5)*
Yes 201 (18.5) 85 (42.3) 116 (57.7) 222 (22.2) 112 (50.5) 110 (49.5)
Depression diagnosis
No 715 (65.7) 170 (23.8) 545 (76.2)* 563 (56.3) 153 (27.2) 410 (72.8)*
Yes 374 (34.3) 117 (31.3) 257 (68.7) 437 (43.7) 165 (37.8) 272 (62.2)
Depression symptoms (DRS score)c
No (\3) 880 (80.8) 199 (22.6) 681 (77.4)* 492 (49.3) 124 (25.2) 368 (74.8)*
Yes (C3) 209 (19.2) 88 (42.1) 121 (57.9) 505 (50.7) 194 (38.4) 311 (61.6)
Delusions/hallucinations
No 999 (91.7) 241 (24.1) 758 (75.9)* 845 (84.5) 233 (27.6) 612 (72.4)*
Yes 90 (8.3) 46 (51.1) 44 (48.9) 155 (15.5) 85 (54.8) 70 (45.2)
Cardiovascular diseased
No 284 (26.1) 94 (33.1) 190 (66.9)* 238 (23.8) 83 (34.9) 155 (65.1)
Yes 805 (73.9) 193 (24.0) 612 (76.0) 762 (76.2) 235 (30.8) 527 (69.2)
Cerebrovascular diseasee
No 823 (75.6) 239 (29.0) 584 (71.0)* 687 (68.7) 230 (33.5) 457 (66.5)**
Yes 266 (24.4) 48 (18.0) 218 (82.0) 313 (31.3) 88 (28.1) 225 (71.9)
No. of co-morbidities
Mean ± SD 4.6 ± 2.0 4.7 ± 2.2 4.6 ± 1.9 5.2 ± 2.0 5.3 ± 2.1 5.2 ± 2.0
0–3 333 (30.6) 103 (30.9) 230 (69.1)* 202 (20.2) 67 (33.2) 135 (66.8)
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Table 1 continued
Characteristic n (%),
unless otherwise noted
DAL residents LTC residents
Total sample
(n = 1089)
Antipsychotic
users (n = 287
[26.4%])
Antipsychotic
non-users
(n = 802 [73.6%])
Total sample
(n = 1000)
Antipsychotic
users (n = 318
[31.8%])
Antipsychotic
non-users
(n = 682 [68.2%])
4 or 5 406 (37.3) 88 (21.7) 318 (78.3) 379 (37.9) 109 (28.8) 270 (71.2)
C6 350 (32.1) 96 (27.4) 254 (72.6) 419 (41.9) 142 (33.9) 277 (66.1)
No. of medicationsf
Mean ± SD 8.0 ± 3.6 7.8 ± 3.5 8.1 ± 3.7 7.6 ± 3.6 7.7 ± 3.4 7.6 ± 3.7
0–6 391 (35.9) 108 (27.6) 283 (72.4) 402 (40.2) 131 (32.6) 271 (67.4)
7–8 242 (22.2) 71 (29.3) 171 (70.7) 208 (20.8) 61 (29.3) 147 (70.7)
9–10 207 (19.0) 50 (24.2) 157 (75.8) 187 (18.7) 63 (33.7) 124 (66.3)
C11 249 (22.9) 58 (23.3) 191 (76.7) 203 (20.3) 63 (31.0) 140 (69.0)
Antidepressants
No 600 (55.1) 121 (20.2) 479 (79.8)* 519 (51.9) 122 (23.5) 397 (76.5)*
Yes 489 (44.9) 166 (33.9) 323 (66.1) 481 (48.1) 196 (40.7) 285 (59.3)
Anxiolytics
No 975 (89.5) 252 (25.8) 723 (74.2) 897 (89.7) 274 (30.5) 623 (69.5)*
Yes 114 (10.5) 35 (30.7) 79 (69.3) 103 (10.3) 44 (42.7) 59 (57.3)
Sedatives/hypnotics
No 844 (77.5) 221 (26.2) 623 (73.8) 801 (80.1) 242 (30.2) 559 (69.8)*
Yes 245 (22.5) 66 (26.9) 179 (73.1) 199 (19.9) 76 (38.2) 123 (61.8)
FI
Robust (FI score\0.2) 366 (33.6) 66 (18.0) 300 (82.0)* 62 (6.2) 14 (22.6) 48 (77.4)*
Pre-frail (FI score 0.2–0.3) 424 (38.9) 99 (23.3) 325 (76.7) 197 (19.7) 26 (13.2) 171 (86.8)
Frail (FI score[0.3) 299 (27.5) 122 (40.8) 177 (59.2) 741 (74.1) 278 (37.5) 463 (62.5)
Falls
None 780 (71.6) 203 (26.0) 577 (74.0) 730 (73.0) 217 (29.7) 513 (70.3)*
C1 falls/90 days 309 (28.4) 84 (27.2) 225 (72.8) 270 (27.0) 101 (37.4) 169 (62.6)
Physical restraints
No 1057 (97.1) 278 (26.3) 779 (73.7) 594 (59.4) 168 (28.3) 426 (71.7)*
Yes 32 (2.9) 9 (28.1) 23 (71.9) 406 (40.6) 150 (36.9) 256 (63.1)
Any inpatient hospitalizations
and/or ED visits (past 90 days)
None 840 (77.1) 229 (27.3) 611 (72.7) 899 (89.9) 290 (32.3) 609 (67.7)
C1 249 (22.9) 58 (23.3) 191 (76.7) 101 (10.1) 28 (27.7) 73 (72.3)
Behavioral characteristics
Aggressive behavior (ABS Score)g
None (0) 771 (70.8) 156 (20.2) 615 (79.8)* 341 (34.1) 63 (18.5) 278 (81.5)*
Moderate (1–2) 183 (16.8) 63 (34.4) 120 (65.6) 203 (20.3) 66 (32.5) 137 (67.5)
Severe to very severe (C3) 135 (12.4) 68 (50.4) 67 (49.6) 456 (45.6) 189 (41.4) 267 (58.6)
Elopement attempts or threats
No 985 (90.4) 234 (23.8) 751 (76.2)* 832 (83.2) 230 (27.6) 602 (72.4)*
Yes 104 (9.6) 53 (51.0) 51 (49.0) 168 (16.8) 88 (52.4) 80 (47.6)
Wandering
No 967 (88.8) 226 (23.4) 741 (76.6)* 770 (77.0) 210 (27.3) 560 (72.7)*
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models for DAL and LTC settings. Among DAL residents,
characteristics significantly associated with antipsychotic
use included a diagnosis of dementia (OR 2.73, 95%
confidence interval (CI) 1.98–3.74 and OR 2.45, 95% CI
1.55–3.86 for untreated [with a cognitive enhancer] and
treated dementia, respectively), diagnosis of a psychiatric
disorder (OR 2.06, 95% CI 1.27–3.33), presence of delu-
sions and/or hallucinations (OR 1.76, 95% CI 0.99–3.14),
being frail (OR 1.92, 95% CI 1.29–2.86), increased length
of stay in DAL (OR 1.66, 95% CI 1.17–2.35 for stays[2
years vs.\1 year), severe aggressive behavior (OR 2.12,
95% CI 1.37–3.29 for ABS scores[2 vs. score = 0), history
of elopement attempts or threats (OR 1.63, 95% CI
1.05–2.54), and concurrent use of antidepressants (OR
1.99, 95% CI 1.43–2.75). Variables significantly associated
with a lower likelihood of antipsychotic use included age
90 years or over (OR 0.64, 95% CI 0.40–1.01) vs. 65–79,
and diagnoses of cardiovascular (OR 0.73, 95% CI
0.54–1.00) or cerebrovascular disease (OR 0.55, 95% CI
0.34–0.89).
With a few exceptions, similar associations between
resident characteristics and antipsychotic use were
observed among LTC residents in fully adjusted models
(Table 3). However, no significant independent association
with use was observed for residents with cardiovascular or
cerebrovascular disease or for those with longer lengths of
stay in LTC. In addition, relative to the youngest age
group, all residents aged 80 years or older showed a sig-
nificantly lower likelihood for antipsychotic use among the
LTC sample. Further, more indicators of behavioral chal-
lenges (in addition to aggressive behavior and elopement
attempts/threats) were retained in the final LTC model,
including wandering (OR 1.48, 95% CI 0.99–2.23) and use
of physical restraints (OR 1.35, 95% CI 0.97–1.89). All the
other psychotropic medications remained significantly
associated with antipsychotic use among LTC residents,
including antidepressants (OR 2.18, 95% CI 1.56–3.05),
anxiolytics (OR 1.82, 95% CI 1.17–2.81), and sedatives/
hypnotics (OR 1.56, 95% CI 1.06–2.28).
Adjusting for resident characteristics and exploring each
of the facility characteristics in separate models, the pres-
ence of designated dementia beds in the facility was sig-
nificantly associated with antipsychotic use in DAL (OR
1.61, 95% CI 1.07–2.44) (Table 4). Conversely, the pres-
ence of a pharmacist on staff (OR 0.48, 95% CI 0.23–1.03),
affiliation with an AL chain (OR 0.57, 95% CI 0.31–1.05),
and facility location in two of the five health regions (OR
0.58, 95% CI 0.35–0.94 and OR 0.56, 95% CI 0.30–1.05
for a mixed urban/rural region and a rural region, respec-
tively, vs. an urban region) were associated with a lower
odds of antipsychotic use. For the LTC setting (Table 4),
following adjustment for resident characteristics, health
region was the only facility variable significantly associ-
ated with antipsychotic use (OR 0.59, 95% CI 0.35–0.97
for region 3 [rural] vs. region 1 [urban]).
The results of the sensitivity analysis revealed fairly
consistent associations between resident and facility char-
acteristics and potentially inappropriate antipsychotic use
across both settings, with a few exceptions (Supplemental
Tables 1 and 2). Among DAL residents, cardiovascular
disease was not significantly associated with potentially
inappropriate use (unlike total antipsychotic use), while
residing in a DAL facility that also offered a higher level of
care (i.e., LTC, acute care) was associated with a lower
likelihood of potentially inappropriate use (OR 0.67, 95%
CI 0.44–1.04). Selected health regions also showed weaker
Table 1 continued
Characteristic n (%),
unless otherwise noted
DAL residents LTC residents
Total sample
(n = 1089)
Antipsychotic
users (n = 287
[26.4%])
Antipsychotic
non-users
(n = 802 [73.6%])
Total sample
(n = 1000)
Antipsychotic
users (n = 318
[31.8%])
Antipsychotic
non-users
(n = 682 [68.2%])
Yes 122 (11.2) 61 (50.0) 61 (50.0) 230 (23.0) 108 (47.0) 122 (53.0)
ABS Aggressive Behavior Scale, AL assisted living, DAL designated assisted living, DRS Depression Rating Scale, ED emergency department, FI
Frailty Index, LTC long-term care, SD standard deviation
* p\ 0.05; ** p\ 0.1
a Dementia treatment defined as use of acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine
b Psychiatric diagnoses defined as a diagnosis of schizophrenia, bipolar disorder, or anxiety
c DRS, 3 LTC residents missing; n = 997
d Cardiovascular diseases defined as diagnoses of hypertension, coronary heart disease, congestive heart failure, peripheral vascular disease,
cardiac dysrhythmia, valvular stenosis, venous thromboembolism, or lipid abnormalities
e Cerebrovascular diseases defined as history of stroke or diagnosis of cerebrovascular disease
f Number of medications excludes antipsychotics
g ABS: a summary scale of four behaviors (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with higher scores
indicating a greater number and frequency of behavioral issues
Prevalence of, and Resident and Facility Characteristics Associated with Antipsychotic Use 45
associations with potentially inappropriate use among
DAL residents. Among LTC residents, use of sedative/
hypnotic drugs and health region were not significantly
associated with potentially inappropriate antipsychotic use
(unlike total antipsychotic use), while residents residing in
a facility with an affiliated physician were significantly less
likely to use potentially inappropriate antipsychotics (OR
0.56, 95% CI 0.32–0.96 and OR 0.46, 95% CI 0.30–0.70
for a physician with an office on site and without an office
on site, respectively, relative to sites with no affiliated
physician).
4 Discussion
Approximately one quarter of DAL residents (26%) were
using antipsychotics, a finding comparable to rates reported
in USA (21%) [51] and France (28%) [48] AL settings.
Table 2 Facility characteristics (DAL vs. LTC), overall and in relation to antipsychotic use (row%)
Characteristic n (%),
unless otherwise noted
DAL residents LTC residents
Total sample
(n = 1089)
Antipsychotic
users (n = 287
[26.4%])
Antipsychotic
non-users (n = 802
[73.6%])
Total
sample
(n = 1000)
Antipsychotic
users (n = 318
[31.8%])
Antipsychotic
non-users (n = 682
[68.2%])
Dementia beds
No 427 (39.2) 74 (17.3) 353 (82.7)* 427 (42.7) 125 (29.3) 302 (70.7)
Yes 662 (60.8) 213 (32.2) 449 (67.8) 573 (57.3) 193 (33.7) 380 (66.3)
Ownership
For-profit 430 (39.5) 121 (28.1) 309 (71.9) 281 (28.1) 96 (34.2) 185 (65.8)
Not-for-profit or RHA 659 (60.5) 166 (25.2) 493 (74.8) 719 (71.9) 222 (30.9) 497 (69.1)
Part of a chain
Not in a chain 159 (14.6) 42 (26.4) 117 (73.6)* 349 (34.9) 103 (29.5) 246 (70.5)
Part of (AL or LTC) chain 343 (31.5) 74 (21.6) 269 (78.4) 320 (32.0) 101 (31.6) 219 (68.4)
Part of AL and LTC chain 587 (53.9) 171 (29.1) 416 (70.9) 331 (33.1) 114 (34.4) 217 (65.6)
Level of care
DAL (LTC) only or DAL
(LTC) ? equivalent/lower
876 (80.4) 244 (27.9) 632 (72.1)* 799 (79.9) 265 (33.2) 534 (66.8)**
DAL (LTC) ? higher 213 (19.6) 43 (20.2) 170 (79.8) 201 (20.1) 53 (26.4) 148 (73.6)
LPN/RN coverage on site
Neither on site 297 (27.3) 63 (21.2) 234 (78.8)*
LPN and/or RN\24/7 118 (10.8) 27 (22.9) 91 (77.1)
LPN and/or RN 24/7 674 (61.9) 197 (29.2) 477 (70.8) 1,000 (100)
Physician (GP) affiliated with site
No 700 (64.3) 189 (27.0) 511 (73.0) 18 (1.8) 6 (33.3) 12 (66.7)
Yes, no office on site 214 (19.7) 52 (24.3) 162 (75.7) 718 (71.8) 220 (30.6) 498 (69.4)
Yes, office on site 175 (16.1) 46 (26.3) 129 (73.7) 264 (26.4) 92 (34.8) 172 (65.2)
Pharmacist involved with site
(past month)
No 366 (33.6) 90 (24.6) 276 (75.4)**
Yes, on staff 29 (2.7) 3 (10.3) 26 (89.7) 393 (39.3) 128 (32.6) 265 (67.4)
Yes, as consultant 694 (63.7) 194 (28.0) 500 (72.0) 607 (60.7) 190 (31.3) 417 (68.7)
Health region
1 (urban) 311 (28.6) 94 (30.2) 217 (69.8)** 296 (29.6) 109 (36.8) 187 (63.2)
2 (mixed urban/rural) 234 (21.5) 57 (24.4) 177 (75.6) 206 (20.6) 63 (30.6) 143 (69.4)
3 (rural) 155 (14.2) 32 (20.6) 123 (79.4) 149 (14.9) 37 (24.8) 112 (75.2)
4 (urban) 281 (25.8) 82 (29.2) 199 (70.8) 239 (23.9) 73 (30.5) 166 (69.5)
5 (rural) 108 (9.9) 22 (20.4) 86 (79.6) 110 (11.0) 36 (32.7) 74 (67.3)
AL assisted living, DAL designated assisted living, GP general practitioner, LPN licenced practical nurse, LTC long-term care, RHA regional
health authority, RN registered nurse
* p\ 0.05; ** p\ 0.1
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Antipsychotic use was slightly higher among LTC resi-
dents (32%) but consistent with the typical range of esti-
mates reported for Canadian LTC settings (29–41%)
[3, 52]. The prevalence estimates observed in both settings
were considerably higher than those reported among
community-dwelling older Canadians (4.4%) [52].
The majority of antipsychotic use in both settings would
be considered potentially inappropriate (80.5 and 70.4% of
use in DAL and LTC, respectively) according to Canadian
guidelines. Although consistent with current Canada-wide
estimates for LTC [53], our observed prevalence of po-
tentially inappropriate antipsychotic use in LTC (26.8%) is
higher than that reported in recent years for LTC sites in
Alberta (e.g., 21% in 2014–2015) [53]. This likely reflects
a reduction in use secondary to targeted initiatives aimed at
reducing antipsychotic use in Alberta LTC since the time
of the ACCES study [54]. However, it is not known whe-
ther the prevalence of antipsychotic use in DAL sites,
which were not included in the initiative, has undergone a
similar reduction. Given their exclusion, there is cause for
concern that the rate of potentially inappropriate antipsy-
chotic use may be unchanged (or even on the rise) in this
care setting.
Similar to previous studies, DAL and LTC residents
with diagnoses of dementia [48–50, 55] psychiatric disor-
ders [48–50, 55, 56], and related behavioral symptoms
Table 3 Adjusted odds ratios (95% confidence intervals) for
antipsychotic use associated with resident characteristics (DAL and
LTC)
Resident characteristic Odds ratio (95% confidence interval)
DAL (n = 1089)a LTC (n = 1000)b
Sociodemographic
Age, years
65–79 (ref gp) 1.00 1.00
80–85 0.72 (0.49–1.06)** 0.65 (0.43–1.00)*
86–89 0.67 (0.42–1.06)** 0.57 (0.34–0.96)*
C90 0.64 (0.40–1.01)** 0.60 (0.38–0.96)*
Sex
Male 1.15 (0.80–1.65) 1.22 (0.87–1.72)
Facility length of stay,
months
\12 (ref gp) 1.00
12–24 1.36 (0.95–1.96)**
[24 1.66 (1.17–2.35)*
Health and functional status
Dementia and treatment
status
No dementia (ref gp) 1.00 1.00
Dementia, not treated 2.73 (1.98–3.74)* 1.97 (1.37–2.84)*
Dementia, treated 2.45 (1.55–3.86)* 3.09 (1.91–5.00)*
Psychiatric diagnoses 2.06 (1.27–3.33)* 2.14 (1.48–3.11)*
Delusions/hallucinations 1.76 (0.99–3.14)** 2.01 (1.35–3.00)*
Cardiovascular disease 0.73 (0.54–1.00)*
Cerebrovascular disease 0.55 (0.34–0.89)*
Antidepressants 1.99 (1.43–2.75)* 2.18 (1.56–3.05)*
Anxiolytics 1.82 (1.17–2.81)*
Sedatives/hypnotics 1.56 (1.06–2.28)*
FI
Robust (FI score\0.2)
(ref gp)
1.00
Pre-frail (FI score
0.2–0.3)
1.18 (0.79–1.74)
Frail (FI score[0.3) 1.92 (1.29–2.86)*
FI (binary)c
Robust/pre-frail (FI
score B0.3)
1.00
Frail (FI score[0.3) 1.82 (1.15–2.87)*
Physical restraints 1.35
(0.97–1.89)**
Behavioral characteristics
Aggressive behavior (ABS
score)
None (0) (ref gp) 1.00 1.00
Moderate (1–2) 1.41 (0.86–2.30) 1.53
(1.00–2.35)**
Severe to very severe
(C3)
2.12 (1.37–3.29)* 2.05 (1.36–3.09)*
Elopement attempts or
threatsd
1.63 (1.05–2.54)* 1.68 (1.07–2.62)*
Table 3 continued
Resident characteristic Odds ratio (95% confidence interval)
DAL (n = 1089)a LTC (n = 1000)b
Wanderingd 1.48
(0.99–2.23)**
ABS Aggressive Behavior Scale, AL assisted living, DAL designated
assisted living, FI Frailty Index, LTC long-term care, ref gp reference
group
a The full multivariable logistic model for DAL adjusts for: age, sex,
dementia/treatment status, psychiatric diagnoses, presence of delu-
sions/hallucinations, frailty status, cardiovascular diagnoses, cere-
brovascular diagnoses, AL length of stay, ABS score, elopement
attempts or threats, and use of antidepressant medication
b The full multivariable logistic model for LTC adjusts for: age, sex,
dementia/treatment status, psychiatric diagnoses, presence of delu-
sions/hallucinations, frailty status, ABS score, elopement attempts or
threats, wandering, use of physical restraints, and use of antidepres-
sant, anxiolytic, and sedative/hypnotic medications
c Because of the small sample of LTC residents found to be robust by
the FI, a binary variable was used for LTC analyses (robust/pre-frail
residents combined for comparison with frail residents)
d Because of collinearity, the variables elopement attempts/threats
and wandering could not be retained together in the fully-adjusted
model for DAL. Elopement attempts/threats was retained in the model
on the basis of its p-value (p = 0.030) compared with wandering (p =
0.044) when included separately in the full model
* p\ 0.05; ** p\ 0.1
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[4, 48–50, 55, 57, 58] (specifically severe aggressive
behaviors and recent elopement attempts/threats, in this
study) were significantly more likely to use antipsychotics
than residents without these conditions. The independent
association observed for residents with dementia (even
after adjusting for, or excluding cases of ‘appropriate use’)
raises concerns about suboptimal prescribing practices and
possible risks for adverse health outcomes in both settings.
Among LTC (but not DAL) residents, use of physical
restraints was also independently associated with antipsy-
chotic use (OR 1.35, 95% CI 0.97–1.89), possibly reflect-
ing the higher prevalence of restraint use in the LTC vs.
Table 4 Adjusted odds ratios
(95% confidence intervals) for
antipsychotic use associated
with facility characteristics
(DAL and LTC)
Facility characteristics (added to
multivariable models one at a time)
Odds ratio (95% confidence interval)
DAL (n = 1089)a LTC (n = 1000)b
Dementia beds 1.61 (1.07–2.44)* 1.03 (0.72–1.48)
Ownership
For-profit (ref gp) 1.00 1.00
Not-for-profit or RHA 0.76 (0.50–1.15) 0.82 (0.57–1.18)
Part of a chain
Not in a chain (ref gp) 1.00 1.00
Part of [AL or LTC] chain 0.57 (0.31–1.05)** 0.98 (0.65–1.47)
Part of AL and LTC chain 0.83 (0.50–1.35) 1.05 (0.69–1.61)
Level of care
Specified level only or specified level
? equivalent/lower (ref gp)
1.00 1.00
Specified level ? higher 0.70 (0.42–1.17) 0.87 (0.52–1.46)
LPN/RN coverage on sitec
Neither on site (ref gp) 1.00
LPN and/or RN\24/7 1.13 (0.57–2.26)
LPN and/or RN 24/7 1.34 (0.88–2.02)
Physician (GP) affiliated with site
No (ref gp) 1.00 1.00
Yes, no office on site 0.97 (0.53–1.77) 0.81 (0.57–1.14)
Yes, office on site 1.01 (0.62–1.64) 0.94 (0.59–1.49)
Pharmacist involved with site (past month)d
No (ref gp DAL) 1.00
Yes, on staff (ref gp LTC) 0.48 (0.23–1.03)** 1.00
Yes, as consultant 1.25 (0.88–1.77) 1.06 (0.75–1.49)
Health region
1 (urban) (ref gp) 1.00 1.00
2 (mixed urban/rural) 0.58 (0.35–0.94)* 1.19 (0.78–1.81)
3 (rural) 0.56 (0.30–1.05)** 0.59 (0.35–0.97)*
4 (urban) 0.80 (0.49–1.30) 1.09 (0.64–1.85)
5 (rural) 0.62 (0.30–1.26) 1.35 (0.71–2.54)
ABS Aggressive Behavior Scale, AL assisted living, DAL designated assisted living, GP general practi-
tioner, LPN licensed practical nurse, LTC long-term care, ref gp reference group, RHA regional health
authority, RN registered nurse
a For DAL, each model adjusts for age, sex, dementia/treatment status, psychiatric diagnoses, presence of
delusions/hallucinations, frailty status, cardiovascular diagnoses, cerebrovascular diagnoses, AL length of
stay, ABS score, elopement attempts or threats, and use of antidepressant medications
b For LTC, each model adjusts for age, sex, dementia/treatment status, psychiatric diagnoses, presence of
delusions/hallucinations, frailty status, ABS score, elopement attempts or threats, wandering, use of
physical restraints, and use of antidepressant, anxiolytic and sedative/hypnotic medications
c All LTC facilities had 24/7 LPN/RN coverage, and thus the LPN/RN coverage variable was only
considered for the DAL analyses
d All LTC facilities had pharmacist involvement as either staff or consultant
* p\ 0.05; ** p\ 0.1
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DAL setting. The combined use of physical restraints and
antipsychotic medications has been linked to a higher risk
of functional and cognitive decline among older adults with
dementia [59]. Should AL facilities continue to evolve as a
preferred residential setting for older adults with dementia
[32], there will be a heightened need to monitor changes in
the prevalence of both inappropriate physical and chemical
restraints.
Although no independent association was identified
between antipsychotic use and length of stay in a French
AL study [48], we found that a greater length of time spent
living in DAL (but not LTC) was positively associated with
antipsychotic use. This observation may be related to
worsening of behavioral symptoms over time among DAL
residents (not detected by the assessment tool). Alterna-
tively, it may point to the relative absence of skilled staff,
ongoing clinical oversight, and prescription reviews in
these facilities [35–37], an issue that has been noted as a
source of concern with respect to potentially inappropriate
medication use [60], including antipsychotic use across
care settings [25, 61].
In a previous study of older patients discharged to res-
idential care from acute care [62], those who were identi-
fied as frail (by the Frailty Index) were at a significantly
increased risk for prescription of potentially inappropriate
medications. Similarly, we found that both DAL and LTC
residents identified as frail were significantly more likely to
use antipsychotics even after adjusting for some of the
clinical components of frailty (e.g., cognitive impairment,
comorbidities). This association may be explained by the
social and functional deficits that are also used to derive the
Frailty Index, as previous studies [50, 55, 57] have reported
positive associations between antipsychotic use and mea-
sures of social isolation and activities of daily living
impairment in LTC. It is also possible that the use of
antipsychotics may have had a role in the development or
worsening of frailty among residents. Because of the cross-
sectional nature of the study, it is not possible to draw
conclusions regarding the direction of these observed
associations. Nevertheless, given the increased risk of
adverse outcomes associated with frailty [63, 64],
antipsychotic use in such vulnerable older residents raises
concerns. Frailty status has been observed to act as an
effect modifier of the association between antipsychotic
use and hospitalization risk, with frail individuals being
more likely than non-frail or pre-frail individuals to be
hospitalized when using antipsychotics [65].
Within both settings, we observed a significant positive
association between the use of antidepressants and
antipsychotics whereas a similar independent association
was not observed for those with a depression diagnosis,
suggesting a tendency toward the use of multiple phar-
macological interventions [66] to manage behavioral
symptoms in DAL and LTC residents. As might be
expected from past research [49], this was most evident
among LTC residents where there was a significantly
increased likelihood of antipsychotic use for those also
using anxiolytics and hypnotics or sedatives.
The inverse association between antipsychotic use and
cerebrovascular disease (also reported in previous studies
[48, 55]) and cardiovascular disease among DAL residents
may indicate a trend toward responsible prescribing deci-
sions given the reported risk of sudden cardiac death [6]
and stroke [7, 8] associated with antipsychotics (although
the association with cardiovascular disease did not remain
statistically significant when considering potentially inap-
propriate antipsychotic use). Similar associations were not
observed among LTC residents, a finding which may point
to less cautious antipsychotic prescribing in LTC, but may
also be explained by the greater complexity of LTC resi-
dents, leading to challenges in optimizing medication use
for individual resident needs.
Contrary to previous US research [49], we found few
significant associations between the various facility level
characteristics and overall antipsychotic use among both
DAL and LTC settings. In this regard, our findings are
more consistent with recent data from residential care
facilities in New Zealand [58]. However, the capacity to
detect facility-level associations in our study and the New
Zealand [58] study may have been limited by the relatively
smaller sample sizes (and potentially lower heterogeneity)
of facilities, relative to the prior US study [49]. The sig-
nificantly lower likelihood for antipsychotic use observed
among residents from DAL facilities located in selected
health regions may reflect unmeasured characteristics of
these facilities given that considerable differences in
antipsychotic prescribing rates have been observed
between different aged care facilities (independent of res-
ident characteristics) in several studies [67–69]. Involve-
ment of a pharmacist on staff in DAL facilities was
independently associated with a lower likelihood of overall
(and potentially inappropriate) antipsychotic use among
residents. Similarly, residents living in a DAL facility that
also offered higher levels of care, and residents of LTC
facilities with an affiliated physician were significantly less
likely to use antipsychotics (when defined as potentially
inappropriate). It seems plausible that direct integration of
highly trained and knowledgeable practitioners into con-
tinuing care facilities (as well as enhanced resident-cen-
tered care) [58] may encourage more responsible and
appropriate use of antipsychotics among residents. As
several of the above facility level factors may be modified,
further targeted interventions to better integrate health care
providers in DAL settings are warranted.
The finding that residents of DAL facilities with desig-
nated dementia beds were significantly more likely to use
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antipsychotics (overall and when defined as potentially
inappropriate) was somewhat unexpected. One might
hypothesize that the presence of such designated spaces
might be associated with the presence of more highly
educated or trained staff with expertise in the appropriate
care of older vulnerable adults with dementia. Interest-
ingly, a recent US study by Kronhaus et al. [56] also found
that among residents with dementia, those residing in AL
facilities with a memory care unit were significantly more
likely to be prescribed antipsychotics than those from
facilities without such a unit. The authors noted that a
plausible explanation for their finding was the increased
likelihood for more aggressive or disruptive behaviors
among those residing in AL facilities with memory care
units. However, our finding of a significant association
between residence in a DAL facility with designated
dementia beds and antipsychotic use, even with adjustment
for the presence and severity of aggressive behaviors and
other relevant clinical characteristics, suggests further
investigation of the importance and impact of dementia
special care units within the AL context may be needed.
Some limitations of our study should be noted. Because
of its cross-sectional nature, no conclusions of causality
can be drawn with respect to the observed associations. The
assessment of antipsychotic use was restricted to active
prescriptions and actual use in the last 3 days, which means
that some residents with potentially relevant exposure (e.g.,
in past week but not in previous 3 days) may have been
misclassified as unexposed at baseline. Similarly, it is not
possible to say whether the findings are representative of
residents’ typical state. The definition of potentially inap-
propriate antipsychotic use employed in our study offers
the opportunity for others to compare our findings with
current reports on potentially inappropriate antipsychotic
use across settings in Canada. However, this definition is
relatively crude and may not reflect appropriate or inap-
propriate use at the actual patient or resident level. Addi-
tionally, data collection for the ACCES study occurred
from 2006 to 2009; consequently, our findings may not
represent the current state of care across AL and LTC in
Alberta. As our study involved residents of designated
(publicly funded) AL facilities in Alberta, the results may
not be generalizable to private AL facilities or those
located outside of Alberta. Our exclusion criteria and
response rates should also be considered, particularly in
relation to the potential limited generalizability of our
findings to relatively more acutely or chronically ill resi-
dents in both settings. At the same time, we believe our
findings are relevant and provide an important addition to
the current knowledge base on antipsychotic use in com-
munity care settings. While acknowledging that changes in
drug patterns may occur over time, our reported prevalence
estimates for antipsychotic use in both settings are
consistent with the current range of estimates noted for
LTC settings across Canada [3, 52, 53]. As there have been
very few studies of antipsychotic use in AL [30, 70], and
none to date in Canada, our prevalence estimates for this
setting also provide an important benchmark to assess
future trends in use as well as the impact of relevant
clinical and/or policy interventions. This is especially
important given that AL is emerging as a particularly
attractive residential care option for older adults with
dementia [31, 32]. Among the 19 studies included in a
recent systematic review on care-delivery interventions to
manage agitation and aggressive in dementia among resi-
dents of AL and LTC [71], only one small study was from
AL and it did not report the impact of the intervention on
antipsychotic use [72]. The associations we observed
between resident and facility characteristics and antipsy-
chotic use are relevant and valid even if there have been
recent changes in the prevalence of use. These observed
associations have direct relevance to other care settings that
may share similar resident, facility, or system characteris-
tics (e.g., in demographics, clinical acuity, staffing, ser-
vices, and clinical oversight).
In addition to providing important baseline data for the
growing AL sector, the sample size, diversity of care set-
tings, and availability of comprehensive resident and
facility-level data (assessed by trained research nurses with
standardized and validated tools) represent important
strengths of our study. Further, we captured actual medi-
cation use by residents rather than relying on drug exposure
data determined by prescription or dispensation claims.
This represents an important strength given the common
use of pro re nata orders for antipsychotics in these settings.
5 Conclusions
Antipsychotic use was observed to be prevalent among
older residents of Alberta DAL (26%) and LTC (32%)
facilities. Further, the proportion of antipsychotic use
considered potentially inappropriate was higher among
DAL than LTC residents. Despite some limited findings
suggesting more cautious prescribing of antipsychotics
among residents with existing (cardiovascular and cere-
brovascular) risk factors in DAL vs. LTC, many of the
resident characteristics significantly associated with
antipsychotic use (including potentially inappropriate use)
among LTC residents were also evident for those in DAL
settings. Of particular concern was the finding of an
increased likelihood of potentially inappropriate antipsy-
chotic use among older and frail residents with dementia
across both settings. Our results suggest that similar to
recent successes in the LTC sector, there may be significant
opportunity to optimize pharmacotherapy and reduce
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inappropriate antipsychotic use within AL settings via
targeted policies aimed at enhancing the availability and
integration of skilled healthcare providers and clinical
services.
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